Optimizing Nilotinib Dose in CML Could Yield Higher Response Rates
Dose optimization of nilotinib is feasible and may help patients with chronic-phase chronic myeloid leukemia achieve molecular responses, according to results of a new study. (Source: CancerNetwork)
Source: CancerNetwork - July 31, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news
CML Patients Approach Normal Life Expectancy With Imatinib Treatment
Treatment with imatinib results in good overall survival in patients with chronic myeloid leukemia, approaching a normal life expectancy, according to the CML-IV study. (Source: CancerNetwork)
Source: CancerNetwork - July 21, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news
FDA Grants Priority Review for New Leukemia Option
The FDA has granted priority review status for two new indications of dasatinib (Sprycel), according to the drug ’s developer. (Source: CancerNetwork)
Source: CancerNetwork - July 20, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Pediatric Cancers Source Type: news
New approach to leukaemia can help improve successful treatment
(University of Liverpool) New University of Liverpool research, presented at an international conference, confirms that a novel approach to the treatment of chronic myeloid leukaemia (CML) can safely increase treatment success and reduce negative side effects. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 12, 2017 Category: Biology Source Type: news
New approach to leukemia can help improve successful treatment
(University of Liverpool) New University of Liverpool research, presented at an international conference, confirms that a novel approach to the treatment of chronic myeloid leukemia (CML) can safely increase treatment success and reduce negative side effects. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 12, 2017 Category: Cancer & Oncology Source Type: news
Treatment-Free Remission in CML Sustainable After Nilotinib
Approximately half of patients with chronic-phase CML who achieved a sustained deep molecular response with nilotinib were able to discontinue therapy and remain in treatment-free remission through 96 weeks. (Source: CancerNetwork)
Source: CancerNetwork - July 6, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia & Lymphoma News Source Type: news
Dasatinib in Children: An Effective Alternative to Imatinib Dasatinib in Children: An Effective Alternative to Imatinib
In children and adolescents with chronic-phase chronic myeloid leukemia, dasatinib shows response rates and safety similar to those seen in adults.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 29, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
TKI De-escalation Safe in Most CML Patients With Major Molecular Response
A de-escalation of tyrosine-kinase inhibitor dose was safe in the majority of patients with chronic myeloid leukemia with stable major molecular response. (Source: CancerNetwork)
Source: CancerNetwork - June 17, 2017 Category: Cancer & Oncology Tags: Chronic Myeloid Leukemia News Source Type: news
Dasatinib Is Safe, Effective in Pediatric Chronic Myeloid Leukemia
Dasatinib was safe and effective in pediatric patients with chronic myeloid leukemia, according to a new study, establishing the agent as a new standard of care for this population. (Source: CancerNetwork)
Source: CancerNetwork - June 13, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Chronic Myeloid Leukemia News Pediatric Cancers Source Type: news
Frontline Bostunib vs Imatinib in Chronic Myeloid Leukemia
This video highlights results of the BFORE trial, which tested bosutinib vs imatinib in newly diagnosed chronic myeloid leukemia patients. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2017 Category: Cancer & Oncology Authors: Jorge E. Cortes, MD Tags: Conferences/ASCO Hematology Chronic Myeloid Leukemia News Videos Hematologic Malignancies Source Type: news
Drug Helps Some Kids With Rare Type of Leukemia
Dasatinib prolonged survival in chronic myeloid leukemia patients, study says (Source: WebMD Health)
Source: WebMD Health - June 5, 2017 Category: Consumer Health News Source Type: news
Cancer Drug Helps Some Kids With Rare Type of Leukemia
Dasatinib prolonged survival in chronic myeloid leukemia patients, study says (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 5, 2017 Category: Cancer & Oncology Tags: Oncology, Pediatrics, Pharmacy, News, Source Type: news
Cancer Drug, Dasatinib, Helps Some Kids With Rare Type of Leukemia
MONDAY, June 5, 2017 -- The cancer drug dasatinib shows promise in treating children with chronic myeloid leukemia (CML) caused by the gene BCR-ABL, also known as the Philadelphia chromosome, researchers report. " Despite the fact that there is a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 5, 2017 Category: General Medicine Source Type: news
Cancer Drug Helps Some Kids With Rare Type of Leukemia
Dasatinib prolonged survival in chronic myeloid leukemia patients, study says (Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - June 5, 2017 Category: Cancer & Oncology Source Type: news
Payments linked to higher odds of doctors prescribing certain cancer drugs
(UNC Lineberger Comprehensive Cancer Center) In preliminary findings (abstract 6510) that will be presented at the American Society of Clinical Oncology Annual Meeting 2017 in Chicago on Saturday, June 3, researchers show that when physicians had to choose between multiple, on-patent drugs for metastatic kidney cancer and chronic myeloid leukemia, they were more likely to prescribe drugs from companies they had received general payments from. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 1, 2017 Category: International Medicine & Public Health Source Type: news
